1. Home
  2. SLN vs TECX Comparison

SLN vs TECX Comparison

Compare SLN & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Silence Therapeutics Plc American Depository Share

SLN

Silence Therapeutics Plc American Depository Share

HOLD

Current Price

$6.57

Market Cap

318.4M

Sector

Health Care

ML Signal

HOLD

Logo Tectonic Therapeutic Inc.

TECX

Tectonic Therapeutic Inc.

HOLD

Current Price

$18.50

Market Cap

359.0M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLN
TECX
Founded
1994
2019
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
318.4M
359.0M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
SLN
TECX
Price
$6.57
$18.50
Analyst Decision
Buy
Strong Buy
Analyst Count
6
5
Target Price
$39.67
$81.20
AVG Volume (30 Days)
314.1K
301.7K
Earning Date
11-06-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$25,830,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
40.39
N/A
52 Week Low
$1.97
$13.70
52 Week High
$8.08
$61.07

Technical Indicators

Market Signals
Indicator
SLN
TECX
Relative Strength Index (RSI) 50.57 45.34
Support Level $5.95 $18.60
Resistance Level $6.60 $20.62
Average True Range (ATR) 0.53 1.46
MACD -0.03 -0.22
Stochastic Oscillator 41.33 5.03

Price Performance

Historical Comparison
SLN
TECX

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

About TECX Tectonic Therapeutic Inc.

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

Share on Social Networks: